The MND is a quite strong promoter and has already been used in previous trials of gamma-retroviral vector GT for adenosine deaminase deficiency (ADA)-SCID (38) and LV GT for adrenoleukodystrophy (ALD) (39, 40). This evidence concerns the gene ADA and adrenoleukodystrophy.